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The role of PIM1/PIM2 kinases in 
tumors of the male reproductive 
system
Manuel Pedro Jiménez-García1, Antonio Lucena-Cacace1, María José Robles-Frías1, 
Maja Narlik-Grassow2, Carmen Blanco-Aparicio2 & Amancio Carnero1
The PIM family of serine/threonine kinases has three highly conserved isoforms (PIM1, PIM2 and 
PIM3). PIM proteins are regulated through transcription and stability by JAK/STAT pathways 
and are overexpressed in hematological malignancies and solid tumors. The PIM kinases possess 
weak oncogenic abilities, but enhance other genes or chemical carcinogens to induce tumors. We 
generated conditional transgenic mice that overexpress PIM1 or PIM2 in male reproductive organs 
and analyzed their contribution to tumorigenesis. We found an increase in alterations of sexual organs 
and hyperplasia in the transgenic mice correlating with inflammation. We also found that PIM1/2 are 
overexpressed in a subset of human male germ cells and prostate tumors correlating with inflammatory 
features and stem cell markers. Our data suggest that PIM1/2 kinase overexpression is a common 
feature of male reproductive organs tumors, which provoke tissue alterations and a large inflammatory 
response that may act synergistically during the process of tumorigenesis. There is also a correlation 
with markers of cancer stem cells, which may contribute to the therapy resistance found in tumors 
overexpressing PIM kinases.
The Proviral Insertion site in Moloney murine leukemia virus proteins (PIM) are a highly evolutionarily con-
served family of serine/threonine kinases composed of three different isoforms (PIM1, PIM2 and PIM3). These 
proteins are regulated primarily through transcription and stability by pathways that are controlled by JAK/STAT 
transcription factors1,2, cytokines, and growth factors involved in hematopoiesis, such as interleukins, GM-CSF 
and G-CSF3,4. In addition, nuclear factor-κ B, Jak-signal transducer and activator of transcription (STAT), 
ETS-related gene and hypoxia-inducible factor-1α are the primary pathways that induce PIM1 upregulation5–8. 
Furthermore, the stability and function of PIM kinases depend on their interaction with heat shock protein 
(Hsp) 909,10, a chaperone involved in the folding and stabilization of different molecules. Hsp90 has been shown 
to not only to protect from ubiquitin-dependent proteasomal degradation but has also been shown to maintain 
the proper conformation of PIM proteins10. The downstream targets of PIM1 signaling are typically regulated by 
direct phosphorylation by PIM1. Thus far, approximately 30 substrates have been shown to interact with and be 
phosphorylated by PIM1. Through phosphorylation of target proteins, PIM1 plays essential roles in the regulation 
of the cell cycle, cell proliferation, anti-apoptosis, multiple drug resistance, chromatin remodeling, protein trans-
lation, energy metabolism, and the stress response11–13. It has been suggested that PIM family members are weak 
oncogenes that can contribute to tumorigenesis by selectively enhancing tumorigenic properties1,2. However, 
PIM family members have also been shown to increase the capacity of other genes or chemical carcinogens to 
induce tumors14–16. The magnitude of the effect varies depending on the affected tissues and the pathways that 
are activated.
Different members of the PIM family of kinases have been found to be overexpressed in hematological malig-
nancies and solid tumors (reviewed at refs 1–4), which led to the idea that these proteins could be potentially 
interesting targets for anticancer drug therapy17–20. PIM1 has been observed to be overexpressed in numerous 
solid tumors5,21–23, including prostate24 and testicular tumors2. Recent studies have correlated PIM1 kinase with 
chemoresistance in prostate cancer cells, which is a common feature of the more aggressive, hormone-refractory 
prostate cancers25,26, and accordingly, the expression of PIM1 correlated with a poor therapeutic outcome27. It has 
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been reported that PIM1 kinase, facilitates cell survival in hypoxia-induced genetic instability in solid tumors and 
resulting in a more aggressive phenotype28. Increased PIM1 expression could partly explain the strong resistance 
of these cancers to chemotherapy29.
Increased PIM2 kinase levels have been detected in acute myeloid leukemia patients and B-cell derived malig-
nancies30,31. Furthermore, PIM2 increased levels have also been shown to be associated with aggressive clinical 
outcome in ABC-DLBCL patients32,33. PIM2 levels have also been found to be elevated in prostate cancers and 
have been correlated with high proliferation rates and decreased apoptosis34.
Aberrant expression of the PIM3 kinase has been observed in malignant tumors of the liver and the pancreas 
as well as. PIM3 has been shown to be highly expressed in Ewing’s sarcoma, hepatocellular carcinoma and pan-
creatic cancer11,35–37. Finally, in some cancers, such as germ cell derived tumors, all three PIM members have 
been found to be overexpressed2. Furthermore, in these cancer types, PIM1 and PIM2 can be overexpressed in 
the same tumors, which suggest that there is only a partial redundancy among them and share some common 
physiological properties.
To characterize the proto-oncogenic role of PIM1/PIM2 in the male reproductive system, we generated 
two MMTV-Cre conditional transgenic mice with confined expression of human PIM1 or PIM2 in 
hormone-dependent tissues. We fully characterized the tumor responses to these genetic alterations in both PIM1 
and PIM2 models, corroborating their role as oncogenes by inducing a hyperproliferation state in tissues of the 
male reproductive system.
Materials and Methods
All methods were performed in accordance with the relevant guidelines and regulations of the Institute for 
Biomedical Research of Seville (IBIS) and University Hospital Virgen del Rocio (HUVR).
Maintenance of mouse colonies. All of the experiments performed using animals received the expressed 
approval from the IBIS/HUVR Ethical Committee for the Care and Health of Animals. All of the animals were 
kept in the IBIS animal facility according to the facility guidelines, which are based on the Real Decreto 53/2013 
and were sacrificed by CO2 inhalation either within a programmed procedure or as a humane endpoint when the 
animals showed significant signs of illness. Efforts were made to minimize suffering wherever possible.
Construction of the transgenic DNA. Human PIM1 and PIM2 cDNAs were cloned into the pVL-1 
vector (Fig. 1A). The DNA construct was linearized and injected into embryonic stem cells. The embryonic 
stem cell injection, selection and transfer were performed by the Transgenic Mice Unit of the CNIO accord-
ing to their standard protocols, as previously described38. Mice born after embryonic stem cell injection were 
genotyped using specifically designed primers, crossed with wild-type (WT) C57/Bl6 mice, and the resultant 
pups were genotyped to verify germ line transmission. Founder mice were then bred, and conditional trans-
gene expression was verified by RT-PCR. Primers designed specifically for human PIM1 and PIM2 kinases, 
which do not amplify mouse Pim genes, were used for all PCR experiments and subsequent genotyping of mice. 
The primers used were, for human genes: PIM1Fw: 5′: CGAGATCGCCATATTTGGTGTCCCCGAG; Rv: 
5′: CCAGCTTGGTGGCGTGCAGGTCGTTGCA; PIM2 Fw: 5′: GGCAGCCAGCATATGGG; Rv: 5′: TAATCCG 
CCGGTGCCTGG. For mouse genes: Pim1 Fw: 5′: CAAGGACGAAAACATCCTTATC; Rv: 5′: GATGGG 
ACCCGAGTGTATAGCC; Pim2 Fw: 5′: GGCAGCCAGCATATGGGC; Rv: 5′: TAATCCGCCGGTGCCTGG.
Necropsy, pathological studies, and immunohistochemistry. Mice were sacrificed by CO2 inha-
lation, and all tissues and tumor samples were immediately dissected and fixed in 10% buffered formalin for 
24 h, dehydrated at different ethanol concentrations with xylol and embedded in paraffin at 65 °C to obtain tissue 
blocks. For histopathological analysis, paraffin blocks were cut into 2.5 μ m sections, mounted and dried on glass 
slides. Sectioned tissues were deparaffinized in xylol, followed by dehydration in graded alcohol solutions and 
were stained with hematoxylin-eosin (H&E).
Histopathologic evaluation of the male reproductive system of mice was performed based on the criteria of 
InHand Project (International Harmonization of Nomenclature and Diagnostic Criteria for lesions in Rats and 
Mice) in relation to proliferative and non-proliferative lesions of the male reproductive system and rat mouse 
(Proliferative and Non Proliferative lesions of the rat and mouse male reproductive system Toxicologic Pathology. 
40: 40S–121S, 2012) and based on the pathologic alterations of the prostate in genetically modified animals: 
classification Bar Harbor (prostate Pathology of Genetically Engineered Mice: Definitions and Classification The 
Consensus report from the Bar Harbor Meeting of the Mouse Models of Human Prostate Cancer Consortium 
Pathology Committee Cancer Research, 64: 2270–2305, 2004).
The inflammatory cell infiltration was assessed as present or absent according to the presence or absence of 
immune cells.
For immunostaining on sectioned tissues, epitope antigen retrieval was performed in sodium citrate (pH 6.5). 
Endogenous peroxidase activity was blocked using DAKO blocking solution for 20 minutes at room temperature. 
Non specific protein binding was saturated using PBS solution containing 10% fetal bovine serum, 1% bovine 
serum albumin and 0.3% Triton X-100 for 1 h at room temperature. Anti-Ki67 (DAKO) antibody was used as 
primary antibody, and the slides were incubated overnight at 4 °C. A secondary antibody anti-goat (ab97100) for: 
CD3 (sc-1127); anti-rat (JI-112-035-003) for: CD45 (NB110-93609), F4/80 (MCA497), and anti-rabbit (JI-111-
035-003) for: Ki67, was applied for 1 h at room temperature, and the immunocomplexes were revealed using sub-
strate buffer and chromogen (Envision, Flex DAKO). The tissues were counterstained with hematoxylin (DAKO), 
rehydrated in a graded alcohol series, and mounted using coverslips. All these procedures were carried out at the 
Histopathology Unit at the IBIS.
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Analysis of relative (RT-PCR) and quantitative (qRT-PCR) expression of PIM1/PIM2 mRNA 
transgenes and immune-dependent mRNAs. Total RNA was isolated from N2 pulverized tissues 
by using miRNeasy kit (Qiagen), treated with DNase (Qiagen), and reverse transcribed with random primers 
and reverse transcriptase (ThermoFisher), according to the manufacturer’s instructions. Reverse transcriptase 
PCR (RT-PCR) was performed to validate tissue specific relative expression levels of either PIM1 or PIM2 (both 
500 pb band) in TgPIM1/TgPIM2 mice. The cDNA was amplified by PCR using specific primer previously men-
tioned. To measure mRNA expression by qRT-PCR we used the following TaqMan Gene Expression Assays 
probes (ThermoFisher) after RT-PCR: PIM1 (Hs01065498_m1), PIM2 (Hs00179139_m1), Pim1 (Mm00435712_
m1), Pim2 (Mm00454579_m1), and endogenous housekeepings: GADPH (Hs03929097_g1) and Gadph 
(Mm99999915_g1). And all immune-related probes: CD4 (Mm00442754_m1), CD8a (Mm01182107_g1), CD74 
(Mm00658576_m1), IFNG (Mm01168134_m1), TAP1 (Mm00443188_m1), TAP2 (Mm01277033_m1), and the 
main HLA in mouse: H2-DMA (Mm00439226_m1), H2-K (Mm01612247_mH), H2-A: (Mm00439211_m1), 
H2-E: (Mm00772352_m1). Real-time PCR was performed using an ABI 7900HT (ThermoFisher). The relative 
mRNA quantities were expressed as 2−∆ Ct. Relative mRNA quantification and statistical analysis of qPCR data 
were conducted using RQ Manager 1.2.1 software (ThermoFisher).
Statistical analysis. All of the grouped data are presented as the mean ± standard error. The differences 
between the groups were assessed by a one- or two-tailed Student’s T-test using GraphPad Prism Software. For 
survival analysis, Kaplan-Meier curves were generated using Prism Software, and a long-rank test was performed 
to determine significant differences between the groups. All of the experiments were repeated in at least duplicate 
Figure 1. The generation and validation of the conditional transgenic MMTV-Cre/PIM1 and MMTV-Cre/
PIM2 murine models. (A) The cDNA sequences of human PIM1 and PIM2 were amplified by PCR using 
specifically designed primers of cDNA from human IMR90 cells as a template. Human PIM1 and PIM2 genes 
were then cloned into the pVL-1 vector, which was a gift from A. Nebreda. The animals carrying the respective 
transgenes for PIM1 or PIM2 were crossed with mice expressing Cre-recombinase under the regulation of the 
MMTV promoter, which resulted in two mouse lines that expressed either PIM1 or PIM2 human transgenes 
exclusively in hormone-dependent tissues. (B) Reverse transcription PCR was performed to validate the 
tissue-specific, relative expression levels of either PIM1 or PIM2 in the transgenic models to confirm transgene 
expression in tissue from the seminal vesicle, prostate, testicle, and brain. (C) DNA obtained from the digested 
tails of the mice was used to genotype the TgPIM1 or TgPIM2 models by PCR. (D) The levels of the human 
PIM1 and PIM2 transgenes and mouse endogenous Pim1 and Pim2 mRNAs were measured by qRT-PCR in 
seminal vesicle (SV), prostate (P) and testicle (T) from both TgPIM1 and TgPIM2 and was compared to WT 
mice. The p-value was obtained using a one-tailed student’s t-test. (*p < 0.05), (**p < 0.01), and (***p < 0.001).
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with triplicate technical replicates for each condition. The data distribution was assumed to be normal, but this 
was not formally tested. The data obtained for retrospective analysis were collected and processed in appropriate 
experimental arms.
Bioinformatic analysis. We analyzed the available, public tumor dataset for PIM kinases expression in 
either testicular seminoma tumors at various stages of progression (GSE8607, Chaganti dataset) or prostate tum-
ors (GSE21034, Sawyer dataset) available at Oncomine (Compendia Biosciences, www.oncomine.org) and R2: 
Genomics analysis and visualization platform (http://r2.amc.nl). For analysis with high and low groups, high 
was defined as greater than one standard deviation above the mean, low is greater than one standard deviation 
below the mean. We also use an independent dataset (GSE3218, Korkola dataset) for adult male germ cell tumors. 
One-way ANOVA was performed to get the statistics. To study both PIM association with chemoresistance and 
immune factors, we used GSE8607 (Chaganti dataset), GSE21034 (Sawyer dataset), and also a tumor prostate 
adenocarcinoma dataset from TGCA (http://cancergenome.nih.gov/), from either PIM1 or PIM2 and the stem/
immune genes activated by their expression, establishing both a stem and a immune PIM dependent signatures. 
Heat-maps are generated by City-block distances.
Results
Generation of transgenic mice carrying the PIM1 or PIM2 transgene. We generated mouse lines 
that express the PIM1 or PIM2 transgene specifically in the male reproductive organs by crossing our PIM1 or 
PIM2 transgenic lines with a transgenic line expressing Cre-recombinase under the MMTV promoter (Fig. 1A). 
The Lox/Stop/Lox cassette was excised by Cre-recombinase allowing transgene expression, which was tested 
using RT-PCR to confirm the specificity (Fig. 1B). Both transgenic lines were expressed only in the seminal vesi-
cles, prostate, testes, and, in a small amount, in the brain (Fig. 1B). To evaluate the specificificity of the transgene 
we genotyped the PIM1 or PIM2 transgene. PIM transgenic cDNA was not detected in WT but was clear in PIM1 
or PIM2 Transgenic mice (Fig. 1C). The levels of transgenic PIM1 or PIM2 mRNAs are around ten/twelve-fold 
higher on average than the levels of endogenous mouse Pim mRNAs (Fig. 1D).
Phenotype of the transgenic mice expressing the PIM1 or PIM2 transgene. To investigate the 
proto-oncogenic role of human PIM1 and PIM2 proteins in male reproductive organs, we generated conditional 
transgenic murine cohorts of male mice that overexpressed either PIM1 or PIM2 transgenes and maintained 
this colony in a controlled environment. Control cohorts without transgene expression were siblings maintained 
under the same conditions. We observed a significant decrease in the average lifespan of the PIM transgenic 
cohorts (Fig. 2A). At the time of death, a macroscopic analysis showed an increase in alterations in the sex organs 
in the transgenic cohort compared to the control cohorts (Fig. 2B). An in-depth microscopic analysis performed 
at necropsy on the sex organs showed a clear increase in tumors in the transgenic mice (Fig. 2C). Specifically, up 
to 60% of the PIM1 and 40% of the PIM2 transgenic mice carried a tumor, while in the WT mice, the percentage 
of animals with tumors did not reach 30%. To reduce the frequency of hematological tumors that normally occur 
in elderly WT mice, we selected 700 days as the end-point. At this time point, both transgenic lines had a statisti-
cally significant increase in the percentage of total tumors compared to WT mice (Fig. 2C).
Following the macroscopic analysis, we performed a microscopic histopathological analysis of the entire male 
reproductive system: testes, epididymis, seminal vesicles, and the prostatic lobes (anterior, dorsolateral, and ven-
tral). We found different grades of both degenerative (testicular tubular atrophy, TTA) and pre-neoplastic lesions 
(Leydig cells hyperplasia, LCH) in all tissues from the testicles that we analyzed from the transgenic models, with 
a slightly higher pre-neoplastic phenotype being observed in the PIM1 mice (Fig. 3A and C).
We further analyzed the proliferation phenotype status in testicle tissues by measuring Ki67 immuno-marker 
levels and found a statistically significant increase in the Ki67 signal in TgPIM1/TgPIM2 mice compared to 
WT mice (Fig. 3A). Conversely, we did not find any relevant disturbances or alterations in tissue from the 
epididymis (data not shown). Interestingly, transgenic mice showed an important inflammatory component in 
the epididymis, testicle, and surrounding tissues (Fig. 3B and D, and Supplementary Figure S1).
Additionally, we also found a pre-neoplastic phenotype in the seminal vesicles and the prostate lobes (Fig. 4). 
We specifically discovered hyper-proliferation and adenoma formation in the epithelial components of the sem-
inal vesicles, which corresponded to the macroscopic results that showed darkening (brown to black) of both 
lobes and the contents of the seminal vesicle as well as a 2–3 time increase in the size of the seminal vesicles 
(Fig. 4A and B). The analysis of the prostate lobes showed that transgenic mice have a statistically significant 
increase in hyper-proliferation of the anterior, dorsolateral, and ventral lobes of the prostate compared to WT 
mice (Fig. 4A and B). Additionally, according to Shappell et al. 2004, classification of prostate neoplasia, they were 
classified as benign hyper-proliferation and also prostate intraductal neoplasia, mPIN, I focal (grade 1).
During the histopathological analysis, we observed a high degree of immune infiltration in the seminal vesicle 
and prostate in both transgenic cohorts but not in the WT mice (Fig. 4C and D, and Supplementary Figure S2). 
This relationship between the expression of the PIM kinases and the mobilization of the immune system was 
strong because it was observed in almost 100% of the transgenic mice.
Together our data indicate that PIM1/PIM2 over-expression induces a pre-neoplastic phenotype in the testi-
cle, seminal vesicles, and prostate, which indicates a possible role in the initiation of oncogenesis in these tissues. 
Furthermore, the presence of inflammation is likely an important second signal contributing to the tumorigenesis.
The relevance of PIM1/2 expression in human male germ cell and prostate tumors. To confirm 
the clinical relevance of PIM kinases expression in human prostate tumors, we analyzed the available public 
tumor dataset for PIM kinase expression. We did not find a clear increase in the overall levels of PIM kinases in 
tumor samples compared to non-tumor tissue from the prostate (Fig. 5A and B). However, it is possible to detect 
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a small subset of prostate tumors with clearly increased levels of these proteins. This subset of tumors with high 
PIM1/2 constitutes approximately 15% of all prostate tumors.
To confirm the clinical relevance of PIM kinases expression in human male germ cell tumors, we analyzed 
the available public tumor datasets (GSE8607, GSE3218) for PIM kinase expression in testicular seminoma tum-
ors at various stages of progression available at Oncomine (Compendia Biosciences, www.oncomine.org) and 
R2: Genomics analysis and visualization platform (http://r2.amc.nl/). We identified that both PIM kinases are 
strongly overexpressed compared to healthy testis specimens and that this overexpression is independent of the 
tumor stage (Fig. 5C). Furthermore, PIM kinases were overexpressed in all tumor types: Seminoma, Teratoma, 
and Yolk Sac tumors (Fig. 5D). Interestingly, seminoma showed the highest levels of PIM1/2 kinase overexpres-
sion in the highest percentage of tumors (Fig. 5D).
PIM1 and PIM2 expression correlates with a pro-inflammatory phenotype in human male 
germ cell and prostate tumors. PIM1/2 kinases are weak oncogenes but undoubtedly attract immune 
cells to the tissue where high expression levels occur (Figs 3 and 4, and Supplementary Figures S1 and S2). To 
address whether a similar increase in inflammatory infiltrates is observed in human male germ cell and prostate 
tumors, we first analyzed the available public male germ cell tumor datasets for PIM expression and correlated 
these results with the inflammatory phenotype. We found a clear correlation between inflammatory markers and 
PIM1/2 expression (Fig. 6A, B and F, and Supplementary Tables S1 and S2). Noticeably, HLAs and membrane 
presentation of antigen molecules were positively correlated in human male germ cell tumors. Most of these 
molecules are common for both PIM1 and PIM2 (29 out of 40), although a small unique subset is found for each 
PIM1/2 proteins.
A similar correlation was observed in prostate tumors. Specifically, 25 out of 35 genes related to antigen pres-
entation were common for both PIM1 and PIM2 overexpressing tumors (Fig. 6C, D and G, and Supplementary  
Figure 2. Phenotype of PIM transgenic mice. (A) Survival of the TgPIM1, TgPIM2, and WT mouse models. 
Both models show a statistically significant reduction in the survival rate compared to the WT mice. (B) Tumor 
incidence in both male models at day 700. The data show the observed macroscopic pathologies in TgPIM1 and 
TgPIM2 mice compared to the WT background, which indicates a statistically significant increase in tumor 
incidence in sex organs (testes, seminal vesicles, and prostate lobes). (C) Total tumor incidence in both models 
at day 700 and the clinical endpoint. This graph shows the total percentage of tumors observed macroscopically 
per model, compared to WT. The p-value was obtained using a Mantel-Cox test (also called a long-rank Chi2 
based test) in (A), and a one-tailed student’s t-test in (B and C). (*p < 0.05), (**p < 0.01), and (***p < 0.001).
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Tables S3 and S4). Interestingly, many of these genes (14 out of 25) were also common for male germ cell tumors 
(Fig. 6B,D and E colored in green).
These data clearly support the relevance of inflammation in tumors with PIM overexpression.
To fully confirm these conclusions, we performed qRT-PCR in PIM tg mice to test whether the inflam-
matory molecules were already expressed in protumor lesions (Supplementary Figures S3 and S4). We found 
clearly expressed HLA antigens in protumoral testis, seminal vesicles and prostate lesions in both transgenic 
mice, PIM1 and PIM2, (Supplementary Figure S3). Furthermore, other inflammatory antigens also present in 
human tumors, such as CD4, CD8a, CD74, IFNg, TAP1 or TAP2, also were activated in mice transgenic lesions 
(Supplementary Figure S4). Interestingly, most of these molecules were more activated in PIM1 than in PIM2 
transgene, coinciding with the relative oncogenic capability found in these mice.
PIM1 and PIM2 expression correlates with stem markers in human male germ cell and prostate 
tumors. It is known that inflammation may trigger dedifferentiation of tumor cells towards a more stem-like 
phenotype. Therefore, we tested whether PIM1 and PIM2 expression is correlated with stem markers in human 
male germ cell and prostate tumors. Furthermore, PIM kinases are strongly associated with chemoresistance, and 
it is possible that factors related to self-renewal and pluripotency such stem-like genes, which are triggered by 
PIM kinases, can partially explain the observed chemoresistance.
To this end, we selected either PIM1 or PIM2 and explored the correlation between the expression of these 
kinases and the expression of stem-like genes activated by their expression. We found a correlation between 
PIM1/2 expression and VENTX, SOX15, UTF1, NANOG, POU5F1P4, POU5F1P3, and POU5F1B expression 
Figure 3. Pathological analysis of the testes from MMTV-Cre/PIM1 and MMTV-Cre/PIM2 transgenic 
models. (A) Pathological analysis of the testes was performed by H&E and Ki67 proliferation marker 
immunostaining of both PIM models, compared to WT. Shown are moderate and high grades of both 
degenerative (testicular tubular atrophy, TTA) and pre-neoplastic lesions (Leydig cells hyperplasia, LCH), 
which were present in only the transgenic models. Also shown is the percentage of Ki67 signal intensity. PS 
indicates Proliferative Status. All scale bars indicate 100 μ m (20X). (B) Representative images of immune 
infiltration (marked with arrows) in germinal tissues (epididymis and testicle) from transgenic mice are shown. 
(C) Pathological abnormalities were examined, and the graph indicates the percentage of degenerative (TTA) 
and Leydig cells hyperplasia in the testicles of both models compared to WT mice. (D) The percentage of mice 
having immune infiltration in germinal organs and nearby tissue structures in transgenic mice was compared 
to WT mice. All of the images were captured using the Microscope Olympus BX-61. The p-value was obtained 
using a one-tailed student’s t-test. (*p < 0.05), (**p < 0.01), and (***p < 0.001).
www.nature.com/scientificreports/
7Scientific RepoRts | 6:38079 | DOI: 10.1038/srep38079
in male germ cell tumors (Fig. 7A and B). When we compared the PIM kinases-derived signature to the adult 
male germ cell tumors dataset (GSE3218), we observed that more than 45% of tumors are positive for the PIM 
kinases-derived signature (Fig. 7A).
In human prostate tumors, it was also possible to detect a small subset of tumors with a clear increase in the 
levels of PIM1/2 transcription. This subset of tumors with high PIM1/2 constitutes approximately 15% of tumors 
and is related to tumors with a stem signature (Fig. 7C and D). In this case, KLF4, KLF10, FOSL2, SERPINE1, 
THBD, MEF2D, and MAFF, showed a clear correlation with increased levels of PIM1/2 (Fig. 7C and D). 
Figure 4. Pathological analysis of the male reproductive system in PIM1/PIM2 transgenic models.  
(A) H&E stating was used to evaluate the pathology of the seminal vesicle as well as the anterior, lateral, and 
ventral prostate lobes in WT and both transgenic models, which revealed normal and hyperproliferative grades, 
respectively. TgPIM1 and TgPIM2 seminal vesicles show areas of epithelial hyperplasia and adenomas. Arrows 
in TgPIM1/TgPIM2 seminal vesicles indicate immune infiltration, which was not found in WT tissues. The 
seminal vesicles scale bars indicates 100 μ m (20X), and the anterior prostate scale bars indicate 200 μ m  
(10X). (B) Following pathological examination of the seminal vesicle and prostate, a higher percentage of 
hyperplastic lesions were observed in both transgenic models compared to WT mice. (C) Immune infiltration 
graph indicating cell infiltration and inflammation phenotypes found in all transgenic mice and WT 
reproductive system samples. All of the images were captured using the Microscope Olympus BX-61. The 
p-value was obtained using a one-tailed student’s t-test (*p < 0.05), (**p < 0.01), and (***p < 0.001).
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Interestingly, while in germ cell tumors, NANOG is a relevant transcript, in prostate tumors, KLF4 is a relevant 
stem marker. This finding along with the different signature found in each tumor type suggests that different 
pathways may be involved in controlling these phenotypes in each tumor type.
These data clearly show that PIM kinases alter the physiology of tumor cells by increasing the stem cell-like 
properties of these cells.
Discussion
To explore the role of PIM1 and PIM2 kinases in cancers of the male reproductive organs, we generated condi-
tional PIM1 and PIM2 transgenic mice that overexpress PIM1 and PIM2 in male reproductive organs, which is 
driven by MMTV-dependent Cre, and analyzed the contribution of these kinases to neoplastic initiation and pro-
gression. We found an increase in alterations in the male sex organs, hyperplasia, and increased proliferation in 
the PIM1 and PIM2 transgenic mice. The overexpression of PIM proteins also correlated with increased immune 
invasion in these tissues. We also found that PIM1 and PIM2 are overexpressed in a subset of human male germ 
cell and prostate tumors and that this overexpression correlated with clear inflammatory features and stem cell 
markers. Therefore, our data suggest that the overexpression of PIM1/2 kinases in the male reproductive organs 
induce tissue organ alterations and a large inflammatory response. This local inflammation may act synergistically 
with PIM kinases intracellular effectors to potentiate the process of tumorigenesis. There is also a correlation with 
markers of cancer stem cells, which may contribute to the therapy resistance found in tumors overexpressing PIM 
kinases.
PIM kinases have been implicated as prognostic factors in several types of cancer24,39. Recent studies have 
also correlated PIM1 kinase expression with chemoresistance in prostate cancer cells, which is a common occur-
rence in more aggressive, hormone-refractory prostate cancers25,26. However, overexpression of PIM1 has only a 
weak oncogenic effect in cells, including cells of the prostate. In a similar model but with PIM expression being 
driven by a PSA-dependent promoter, the combination of PIM1 with hormone treatment, or in combination with 
reduced PTEN levels, induced more frequent mPIN lesions and lesions of a higher grade38.
Similar to other transgenic or knockout models40–43, our model showed that increased expression of PIM1/2 
alone, driven by the viral promoter MMTV, was not sufficient to produce adenocarcinoma; however, PIM expres-
sion clearly contributed to the observed increase in hyperplasia and other precancerous lessions. This finding is 
consistent with reports on cell lines that showed PIM overexpression alone was not sufficient to induce malignant 
Figure 5. The role of PIM overexpression in male germ cell and prostate tumors. (A) Analysis of GSE21034 
(Prostate tumor) for PIM1/2 relative expression. (Normal Prostate (NP) n = 70; Primary tumor (T) n = 262; 
PIM1 p = 0.06; PIM2 p = 0.05, by an unpaired t-test). (B) Patients were classified into groups based on the 
PIM1/2 gene expression level. (C) Analysis of available, public tumor datasets for PIM kinases expression in 
either testicular or seminoma tumors at various stages of progression (GSE8607) available at Oncomine and R2 
platform. High and low groups were defined as above and below the mean, respectively. For analysis of the high 
and low groups, high was defined as greater than one standard deviation above the mean, and low was defined 
as greater than one standard deviation below the mean. In total, 43 samples were segregated onto Normal 
testis, pT1, pT2, and pT3. One-way ANOVA was performed to determine the statistical significance. PIM1: 
pT1, p = 0.0002***; pT2, p < 0.0001****; pT3, p = 0.0192*. PIM2: pT1, p = 0.0489*; pT2, p = 0.0180*; pT3, 
p = 0.0403*. (D) Analysis of PIM kinases expression levels in an independent dataset (GSE3218) of adult male 
germ cell tumors, compared to healthy tissue (NT), Seminoma (S), Teratoma (TER), and Yolk Sac (YS) tumors.
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Figure 6. PIM overexpression correlates with an immune system-dependent genes signature in male germ 
cell tumors. (A) A Venn diagram showing the number of immune system-dependent genes that correlated with 
PIM1 or PIM2 overexpression in male germ cell tumors. (B) A list of system-dependent genes in male germ cell 
tumors that correlated with both PIM1 and PIM2 overexpression (common) or that was unique to either PIM1 or 
PIM2. (C) A Venn diagram showing the number of immune system-dependent genes that correlated with PIM1 or 
PIM2 overexpression in prostate tumors. (D) A list of system-dependent genes in prostate tumors that correlated 
with both PIM1 and PIM2 overexpression (common) or that was unique to either PIM1 or PIM2. (E) A Venn 
diagram showing the number of common immune system-dependent genes that correlated with PIM1 or PIM2 
overexpression in male germ cell and prostate tumors. (F) The figure shows a heat map comparing immunology-
related genes with PIM1 (See Supplementary Table S1) and PIM2 (See Supplementary Table S2). PIM1 and PIM2 are 
statistically increased in the analyzed dataset for male germ cell tumors (GSE21034) (PIM1 p = 0.06, PIM2 p = 0.05) 
(Control sample n = 70, Primary tumor n = 262. Unpaired t-test). We observed that approximately 45% of the 
patients had overexpression of either PIM1 or PIM2 in their tumors compared to the control. (G) The figure shows 
two heatmaps from different databases (GSE21034, and TCGA datasets) comparing immunology-related genes 
in prostate tumors with PIM1 (See Supplementary Table S3) and PIM2 (See Supplementary Table S4). Although 
neither PIM1 nor PIM2 are statistically increased in the analyzed dataset for prostate tumors (PIM1 p = 0.06, PIM2 
p = 0.05) (Control sample n = 70, Primary tumor n = 262. Unpaired t-test), we observe that approximately 15% of 
the patients had overexpression of either PIM1 or PIM2 in their tumors compared to the control.
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transformation of benign cells but did enhance the in vitro and in vivo tumorigenic capabilities of tumor cells44,45. 
Similarly, mice expressing PIM1 in T-cells were more susceptible to carcinogenesis-induced T-cell lymphoma16,46. 
Figure 7. The correlation between PIM overexpression in human male germ cell and prostate tumors and 
the stem-dependent genes signature. (A) A heat map of the PIM kinases-derived signature in the adult male 
germ cell tumors dataset (GSE3218). This dataset shows a percentage of the patients with a clear positive PIM 
kinases-derived stem signature, which included more than 45% of patients (Heat-map is sorted by City-block 
distances). (B) Analysis of the correlation between PIM1/2 overexpression and factors related to self-renewal 
and pluripotency, such stem-like genes in germ cell tumors. To study this, we analyzed the correlation between 
PIM1/2 expression and stem-like gene expression and found a significant positive correlation with VENTX, 
SOX15, UTF1, NANOG, POU5F1P4, POU5F1P3, and POU5F1B. (C) The figure shows a heat map of the 
correlation between PIM1/2 expression in human prostate tumors and the previous stem-like gene signature. 
(D) Analysis of the correlation of PIM1/2 overexpression with factors related to self-renewal and pluripotency, 
such stem-like genes in prostate tumors. To this end, we analyzed the correlation between PIM1/2 expression 
and stem-like gene expression and found a significant positive correlation with KLF4, KLF10, FOSL2, 
SERPINE1, THBD, MEF2D, and MAFF.
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It has also been reported that transgenic mice selectively expressing human PIM3 in the liver have an increased 
frequency and decreased latency of hepatocellular carcinoma induced by the carcinogen diethylnitrosamine47. 
Combined with our data, these studies suggest that while PIM family members are weak oncogenes, they can 
contribute to tumorigenesis by selectively enhancing tumorigenic capabilities related to progression process.
The overexpression of PIM proteins clearly correlated with an increase in immune cell invasion in these tis-
sues. We also found that PIM1 and PIM2 are overexpressed in a subset of male germ cell and prostate tumors 
and that this overexpression correlated with clear inflammatory features and stem cell markers. Therefore, our 
data suggest that the overexpression of PIM1/2 kinases is a common feature of tumors of the male reproductive 
organs due to tissue organ alterations and a large inflammatory response, which may act synergistically during 
the process of tumorigenesis. It is possible that the expression of the PIM proteins acts as an immune chemoat-
tractant, and this immune presence then triggers neoplastic alterations. Therefore, the weak effect of PIM onco-
genes observed in vitro might be due to the absence of complementary signals that could potentially occur in the 
presence of inflammation.
In this context, enhanced local inflammation could be a tumor promotion mechanism led by high levels of 
PIM and inducing the activation of the JAK/STAT signaling pathway. STAT proteins have been linked to the 
control of the development of hematopoietic cells involved in inflammation, and mediating the responses of 
target cells to inflammatory cytokines. This has been corroborated in several PIM-dependent in vitro and in vivo 
models48,49. PIM1 appears to contribute to NFκ B activation upon TNF-α activation50 through a feedback 
loop, while PIM1-inhibitors prevent NFκ B activation and decrease iNOS production in macrophages and 
decrease levels of TNFα . In this regard, high PIM levels increase the recruitment of tumor/inflamma-
tion associated macrophages, MDSCs, mast cells, and neutrophils to the target tissue, which can increase 
cytokines, such as IL-6, IL-1 and TNFa, and chemokines, such as CCL2 and CXCL8, locally. This local 
increase of cytokines surrounding tumor cells might collaborate in tumorigenesis by activating the NFkB 
and/or STAT3 pathways51.
We reported here that the high levels of PIM kinases correlated in human tumors with some pluripotency 
related genes such as NANOG, SOX15 or KLF4 (Fig. 7). This is consistent with other works describing that PIM 
phosphorylates and enhances OCT4 and MYC, which also contributes to the reprogramming of tumor cells8,52. 
Furthermore, other PIM-dependent pathways promoting the self-renewal of stem cells have been reported53–56. 
PIM kinases might influence self-renewal and reprogramming through direct phosphorylation of BCRP/ABCG2, 
a putative stem cell marker, which may be involved in multiple drug resistance57. PIM kinases might regulate 
androgen receptor (AR) turnover by phosphorylation58. Therefore, PIM1-dependent phosphorylation of AR reg-
ulates gene transcription, especially STAT3, which is prevalent in aggressive prostate cancer27,59. This effect of PIM 
proteins on AR may influence stem cell renewal mediated by STAT357.
PIM may also influence the cancer stem cell-related phenotype by the recruitment of local inflammation 
observed in the tumor microenvironment. Inflammatory cytokines such as IL-1, IL-6, and IL-8 may be induced 
by monocytes and macrophages recruited by the tumor, and may regulate cancer stem cell self-renewal in their 
niches. These cytokines activate the STAT3/NF-κ B pathways in tumor and stromal cells generating positive feed-
back loops that contribute to CSC self-renewal60. Growth receptors and their ligands, such as HER2, EGFR, or 
EGF, activate NFκ B, and the pro-inflammatory cytokine IL-6 activates both NFκ B and STAT361. Elevated levels 
of IL-6 have been linked to decreased survival in breast, pancreatic, gastric, prostate, and lung cancers. Moreover, 
chemokine receptors and their ligands are frequently expressed in malignant cells. For example, the levels of the 
chemokine receptor CXCR4 correlate with the ability of primary tumors to metastasize62. The relevance of inflam-
mation in CSC physiology comes from the observation that non-CSCs may revert to a stem cell-like state, even 
in the absence of DNA mutations, which confirms that the microenvironment is able to regulate the stem-like 
properties of cells63.
Inflammation is not only essential to cancer induction by its mutagenic effects but also for the long-term sur-
vival of the tumors by influencing the microenvironment. Activation of the NFκ B and STAT3 pathways remove 
the immune mask set by the CSC64. It has been proposed that the tumorigenic potential of CD14+ cells is due 
to their expression of several inflammatory mediators, such us IL-6, IL-8, FGF-2, and VEGF-165. In this regard, 
there is evidence of a role for PIM1 in iPS through the IL-6/STAT3 pathway, which enhances the proliferation of 
mesenchymal stem cells66. Furthermore, in PIM1 transgenic mice, the number of Lin− /Sca+ /cKit+ hematopoi-
etic stem/progenitor cells was increased compared to normal mice67. Therefore, PIM kinases may serve to attract 
inflammatory cells and induce stem cell self-renewal, which may engage in a positive feedback loop increasing the 
tumorigenic potential of tumor cells that overexpress PIM kinases.
In summary, PIM kinases are overexpressed in a large variety of human tumors. Both in vitro and in vivo 
studies have demonstrated that PIM kinases behave as oncogenes by enhancing tumor cell proliferation and 
protecting from apoptosis. We fully characterized the tumor response to PIM1/2 overexpression in transgenic 
mouse models, which corroborated their role as weak oncogenes by inducing a hyperproliferation state in the 
tissue of the male reproductive system. Furthermore, we found a high inflammatory response associated with 
PIM expression. The analysis of human germ cell and prostate tissues showed that PIM overexpressing tumors 
are also associated with an increased immune response and the presence of stem cell markers. We propose that 
PIM kinases induce a pro-inflammatory microenvironment that cooperates with PIM kinases in the tumorigenic 
process by either directly or indirectly modifying the CSC pool.
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